



University of Dundee

Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity

Jeacock, Laura; Baker, Nicola; Wiedemar, Natalie; Mäser, Pascal; Horn, David

Published in:
PLoS Pathogens

DOI:
[10.1371/journal.ppat.1006307](https://doi.org/10.1371/journal.ppat.1006307)

Publication date:
2017

Document Version
Final published version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Jeacock, L., Baker, N., Wiedemar, N., Mäser, P., & Horn, D. (2017). Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity. *PLoS Pathogens*, 13(3), 1-16. [e1006307]. DOI: [10.1371/journal.ppat.1006307](https://doi.org/10.1371/journal.ppat.1006307)

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH ARTICLE

Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity


Laura Jeacock^{1‡}, Nicola Baker^{1‡}, Natalie Wiedemar^{2,3}, Pascal Mäser^{2,3}, David Horn^{1*}

1 The Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee, United Kingdom, **2** Parasite Chemotherapy Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland, **3** University of Basel, Basel, Switzerland

✉ Current address: Centre for Immunology & Infection, University of York, Heslington, York, United Kingdom

‡ These authors are co-first authors.

* d.horn@dundee.ac.uk



 OPEN ACCESS

Citation: Jeacock L, Baker N, Wiedemar N, Mäser P, Horn D (2017) Aquaglyceroporin-null trypanosomes display glycerol transport defects and respiratory-inhibitor sensitivity. *PLoS Pathog* 13(3): e1006307. <https://doi.org/10.1371/journal.ppat.1006307>

Editor: Scott M Landfear, Oregon Health & Science University, UNITED STATES

Received: December 4, 2016

Accepted: March 22, 2017

Published: March 30, 2017

Copyright: © 2017 Jeacock et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This research was jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, and is also part of the EDCTP2 programme supported by the European Union (MR/K000500/1 to DH), by the Wellcome Trust (100320/Z/12/Z; Investigator Award to DH), and by the Swiss National Science

Abstract

Aquaglyceroporins (AQPs) transport water and glycerol and play important roles in drug-uptake in pathogenic trypanosomatids. For example, AQP2 in the human-infectious African trypanosome, *Trypanosoma brucei gambiense*, is responsible for melarsoprol and pentamidine-uptake, and melarsoprol treatment-failure has been found to be due to AQP2-defects in these parasites. To further probe the roles of these transporters, we assembled a *T. b. brucei* strain lacking all three AQP-genes. Triple-null *aqp1-2-3 T. b. brucei* displayed only a very moderate growth defect *in vitro*, established infections in mice and recovered effectively from hypotonic-shock. The *aqp1-2-3* trypanosomes did, however, display glycerol uptake and efflux defects. They failed to accumulate glycerol or to utilise glycerol as a carbon-source and displayed increased sensitivity to salicylhydroxamic acid (SHAM), octyl gallate or propyl gallate; these inhibitors of trypanosome alternative oxidase (TAO) can increase intracellular glycerol to toxic levels. Notably, disruption of AQP2 alone generated cells with glycerol transport defects. Consistent with these findings, AQP2-defective, melarsoprol-resistant clinical isolates were sensitive to the TAO inhibitors, SHAM, propyl gallate and ascofuranone, relative to melarsoprol-sensitive reference strains. We conclude that African trypanosome AQPs are dispensable for viability and osmoregulation but they make important contributions to drug-uptake, glycerol-transport and respiratory-inhibitor sensitivity. We also discuss how the AQP-dependent inverse sensitivity to melarsoprol and respiratory inhibitors described here might be exploited.

Author summary

Protein channels in cell membranes transport specific molecules in and out of cells, and can also facilitate drug-uptake. One such protein, known as an aquaglyceroporin (AQP), allows parasitic African trypanosomes, the cause of lethal diseases in humans and livestock, to accumulate an arsenic-based drug known as melarsoprol. Unfortunately,

Foundation (310030_156264). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

parasites with a mutated AQP have resisted this drug and have spread, leading to treatment-failure in >50% of patients in some areas. The functions of this particular AQP, and two other similar AQPs normally expressed by these parasites, remain to be fully characterised in trypanosomes. We therefore generated and characterised parasites lacking all three AQPs. The cells grow well and, to our surprise, continue to effectively allow water to flow in and out of the cell. Glycerol uptake and efflux are both perturbed, however. As a consequence, drugs that cause these parasites to produce toxic quantities of glycerol are more effective against parasites lacking the AQPs. Indeed, even the melarsoprol-resistant, patient-derived parasites described above are more sensitive to these drugs. Our findings not only reveal the relative contributions of the AQPs to glycerol transport, they also point to therapies that could be more effective in the many patients infected by melarsoprol-resistant parasites.

Introduction

African trypanosomes are parasitic protozoa and the causative agents of human and animal African trypanosomiasis (HAT and AAT, respectively). These parasites are typically transmitted by tsetse-flies, which are restricted to sub-Saharan Africa. HAT is typically fatal without treatment, classified as a 'neglected tropical disease', and caused primarily by *T. brucei gambiense* (Western-Africa) but also by *T. brucei rhodesiense* (Eastern Africa). AAT is typically caused by *T. vivax*, *T. congolense* or *T. b. brucei*, important veterinary and livestock pathogens; *T. b. brucei* is a less-prevalent veterinary parasite and the favoured experimental sub-species. Vaccine development is challenging and therapies suffer problems with toxicity, resistance, cost, limited efficacy and difficulties with administration [1]. In addition, in the case of HAT, diagnostic tools must define the stage of the disease if the appropriate therapy is to be selected [1]. For treatment of the second stage for example, when parasites have entered the central nervous system, the nifurtimox-eflornithine combination therapy is favoured [2]. The other option is melarsoprol, but this is toxic [1]. Unfortunately, eflornithine is ineffective against *T. b. rhodesiense* [3] so melarsoprol is currently the only option, despite its toxicity, against advanced disease caused by this parasite.

Melarsoprol treatment-failure, in >50% of patients in some areas, has been reported for both *T. b. rhodesiense* [4] and *T. b. gambiense* infections [5]. Melarsoprol-resistance can arise due to reduced accumulation of drug, following aquaglyceroporin 2 (AQP2) mutation [6]. Both a trypanosome P2 adenosine transporter [7,8] and AQP2, an aquaglyceroporin with an unusual arrangement of pore-lining residues comprising the 'selectivity filter' [9,10], contribute to melarsoprol-uptake; laboratory-engineered defects in these transporters render cells melarsoprol-resistant. These cells also display cross-resistance to pentamidine [6], a drug used to treat trypanosomiasis prior to central nervous system involvement. This may have little impact in the clinic, however, because pentamidine remains effective at the high doses administered [11]. In terms of melarsoprol-resistance and treatment-failure, clinical isolates from both the Democratic Republic of the Congo and South Sudan, dating back to the 1970s, display AQP2-defects [12,13], and a clinical isolate was re-sensitised to both melarsoprol and pentamidine by the addition of an intact AQP2 gene [14]. A defect in a related *Leishmania* AQP has been linked to widespread antimonial-resistant *Leishmania* infections in India [15].

There are three AQPs encoded in the *T. b. brucei* genome. AQP1 has been reported to localise to the flagellar membrane in bloodstream-form cells [16], while plasma membrane localisation is indicated in insect-stage cells [17]. AQP3 displays a plasma membrane localisation in

both bloodstream-form cells [9,16] and insect-stage cells [9]. AQP2, on the other hand, is largely restricted to the flagellar pocket membrane in bloodstream-form cells, and then becomes distributed more widely in the plasma membrane in insect-stage cells [9]. Heterologous expression of the *T. b. brucei* AQPs reveals their ability to transport water, mass: 18 Da; ammonia, mass: 17 Da [18]; boric acid, mass: 62 Da [19]; glycerol, mass: 92 Da [20] and some forms of trivalent arsenic, mass: 83–198 Da; and trivalent antimony, mass: 122–292 Da [21]. AQP2 gene-knockout in *T. b. brucei* reveals that this AQP can also specifically mediate uptake of melarsoprol; mass: 398 Da, and pentamidine; mass: 340 Da [9,10]. These drugs have a substantially greater mass than other known AQP-substrates and recent evidence indicates that pentamidine, rather than being a permeant, binds to and inhibits AQP2, suggesting that uptake of this drug might require endocytosis [22].

To further probe AQP-function, we deleted all three *T. b. brucei* AQP genes from the *T. b. brucei* genome. We found that trypanosomes tolerate the loss of all three AQPs. The triple *aqp1-2-3* null-strains, surprisingly, tolerated hypotonic shock, but were defective in glycerol uptake, utilisation and efflux and, consequently, were sensitised to trypanosome alternative oxidase (TAO) inhibitors that increase the intracellular glycerol concentration to toxic levels. Notably, trypanosomes lacking only AQP2 were also defective in glycerol utilisation and efflux and, as predicted by our *T. b. brucei* studies, clinical melarsoprol-resistant *T. b. gambiense* isolates were also more sensitive to respiratory inhibitors relative to melarsoprol sensitive reference strains.

Results

T. b. brucei tolerates the loss of all three AQPs

T. b. brucei AQP1 (Tb927.6.1520) is on chromosome 6 and AQP2 (Tb927.10.14170) and AQP3 (Tb927.10.14160) are adjacent to each other on chromosome 10 (see Fig 1A). The AQP2-AQP3 locus is dispensable for growth [23]. AQP1 knockdown, using RNA interference was not associated with any substantial growth-defect [16], but knockout of AQP1 has not, to our knowledge, been attempted. *T. b. brucei* is diploid so we sequentially replaced the AQP1 alleles with selectable markers (*NPT* and *PAC*) to determine whether AQP1 was dispensable (see Fig 1A). We readily obtained *aqp1*-null strains, as confirmed by Southern blotting (Fig 1B).

We next devised a strategy to assemble triple *aqp*-null strains in a background that would facilitate conditional expression of wild-type or mutant AQPs for complementation studies. In order to recycle the limited number of selectable-markers available, we used a multi-step strategy employing the meganuclease, I-SceI (see Materials and methods). Briefly, we set up strains in the 2T1-background [24] in which meganuclease induction triggered the replacement of a chromosomal knockout-cassette, bearing an I-SceI cleavage-site, with an allelic knockout-cassette lacking an I-SceI cleavage-site. The cassette-integration and chromosomal allele-replacement process was carried out for the AQP2-AQP3 locus and then repeated for the AQP1 locus, such that the resulting strains bore a *BLA*-marker at both *aqp2-aqp3* null alleles and an *NPT*-marker at both *aqp1* null alleles (Fig 1A). Southern blotting confirmed the absence of AQP1 (Fig 1B), AQP2 and AQP3 (Fig 1C) in the resulting *aqp1-2-3* null strains. Thus, *T. b. brucei* tolerates the loss of all three AQPs.

The *T. b. brucei* AQPs have minimal impact on fitness or osmoregulation

We assessed fitness in cell-culture for the new *aqp1* and *aqp1-2-3* strains and compared these to the wild-type and the previously described *aqp2-3* strains [9]. The growth-curves indicated a modest defect in the *aqp1-2-3* strains and no apparent defect in the *aqp1* or in the *aqp2-3* strains (Fig 2A). The *aqp1-2-3* strains were also able to establish infections *in vivo* in a mouse




Fig 1. *T. b. brucei* tolerates the loss of all three AQPs. (A) The schematic maps indicate the *AQP1* and *AQP2-3* regions replaced by selectable markers as also indicated on the right. Δ indicates the regions deleted while the probes used for Southern blotting are shown above the maps. H, *Hpa*I; S, *Sac*I. (B) The Southern blots indicate deletion of the *AQP1* alleles in *aqp1* and three independent *aqp1-2-3* strains. Wild-type (WT) is shown for comparison. Genomic DNA was digested with *Hpa*I. (C) The Southern blots indicate deletion of the *AQP2-3* alleles in *aqp1-2-3* strains. WT is shown for comparison. Genomic DNA was digested with *Sac*I.

<https://doi.org/10.1371/journal.ppat.1006307.g001>

model; parasitaemia in all three mice was between 4×10^6 and 4×10^7 per ml of blood four days after inoculation. These *aqp1-2-3* strains also differentiated to the insect mid-gut stage *in vitro*; equivalent to wild-type after one week in insect-stage growth-medium. Thus, we observed only a modest fitness-defect in bloodstream-form cells in the absence of all three AQPs but not in the absence of either *AQP1* or *AQP2-AQP3*.

AQP2 specifically controls melarsoprol and pentamidine-uptake and has a particularly pronounced impact on pentamidine-sensitivity *in vitro* [9]. Dose-response assays confirmed the expected pentamidine-resistance in the *aqp2-3* strains and indicated no additional resistance in the *aqp1-2-3* strains (Fig 2B); EC₅₀-values were increased by approximately 30-fold relative to wild-type in both cases. These results are consistent with the established specific role for *AQP2* in pentamidine (and melarsoprol) uptake and cross-resistance [9,12,23].

AQPs can transport water or small solutes. To explore the contribution of the *T. b. brucei* AQPs to osmoregulation, we exposed cells to hypo-osmotic shock and monitored the response. Under these conditions, cells swell rapidly and then, more slowly (10–20 min), return to their original volume. We saw no, or only moderate, differences in the time taken to recover for *aqp1*, *aqp2-3* or *aqp1-2-3* null-cells relative to wild-type trypanosomes (Fig 2C). We conclude that the *T. b. brucei* AQPs have minimal impact on fitness or regulatory volume-decrease after osmotic shock.

Glycerol uptake and utilisation are perturbed in *aqp* null *T. b. brucei*

We next assessed the ability of the *aqp1-2-3* null *T. b. brucei* strains to use glycerol as a carbon-source, which is possible in bloodstream form trypanosomes under aerobic conditions [25]. In preliminary experiments, *aqp1-2-3* cells displayed sustained motility in 5 mM glucose and




Fig 2. The *T. brucei* AQPs have minimal impact on fitness or osmoregulation. (A) Cumulative growth-curves for wild-type (WT), *aqp1*, *aqp2-3* and *aqp1-2-3* null-strains. (B) Dose-response curves for pentamidine. (C) Hypo-osmotic shock assay. Open symbols, Earle's salt buffer; filled symbols, buffer diluted 50:50 with H₂O. The recovery phase is shown. The phase-contrast images show two shocked and swollen cells (at left) and a recovered cell (at right). Scale-bar, 5 μm. DNA was counter-stained with DAPI (blue).

<https://doi.org/10.1371/journal.ppat.1006307.g002>

fructose but these cells were immotile within 15-minutes in 5 mM glycerol. To quantify the ATP-levels in cells incubated in 5 mM glucose or glycerol, we used a luminescence assay and this confirmed that *aqp1-2-3* cells were able to use glucose as a carbon-source but were unable to utilise glycerol (Fig 3A). Since ATP-levels were significantly depleted ($P < 0.001$) relative to wild-type in *aqp1-2-3* cells incubated in glycerol, we exploited this assay to assess the impact of the various AQPs on glycerol utilisation; cells were harvested before they became immotile in this assay so as to record quantitative differences among strains. As expected, ATP-levels were not significantly diminished in any of the *aqp*-defective strains tested in glucose (Fig 3A). In glycerol though, ATP-levels were significantly depleted ($P < 0.001$) in *aqp2*, *aqp2-3* and *aqp1-2-3* cells but not in *aqp1* cells (Fig 3A). These results suggest that, among the AQPs, AQP2 makes the greatest contribution to glycerol utilisation; this interpretation is supported by both effective utilisation of glycerol by *aqp1* null cells and no increase in the glycerol-utilisation defect in *aqp2-3* cells relative to *aqp2* cells.

Since glycerol utilisation does not directly reflect glycerol uptake, we next measured glycerol uptake; in wild-type, triple-null and AQP2-complemented cells. The *aqp1-2-3* cells




Fig 3. Glycerol uptake and utilisation is perturbed in *aqp*-null *T. b. brucei*. (A) ATP levels were assessed in the strains indicated after incubation in 5 mM glucose or glycerol. Readings were taken in triplicate and normalised to substrate only. * indicates significantly different ($P < 0.001$) to wild-type (WT) using an ANOVA test in GraphPad Prism. Error bars, SD. (B) Radiolabelled glycerol uptake was assessed in the strains indicated. Readings were taken in quadruplicate. * indicates significant difference ($P < 0.05$) using a Student's *t*-test. Error bars, SD.

<https://doi.org/10.1371/journal.ppat.1006307.g003>

revealed almost complete ablation of glycerol-uptake (Fig 3B), consistent with minimal diffusion of glycerol across the plasma membrane. AQP2 provided complementation of this defect, albeit only partial (Fig 3B). Thus, AQP2 appears to make the greatest contribution to glycerol utilisation but not the major contribution to glycerol uptake into the cell, possibly reflecting an impact on transport into glycosomes, where glycerol is utilised [25].

T. b. brucei aqp-null cells display a glycerol efflux defect and respiratory inhibitor-sensitivity

We next asked whether *aqp*-defective trypanosomes displayed glycerol-efflux defects as well as the glycerol-uptake defects described above. Salicylhydroxamic acid (SHAM) increases intracellular glycerol levels by inhibiting the trypanosome alternative oxidase (TAO) [26], a ubiquinol oxygen oxidoreductase that is cyanide-insensitive and maintains redox balance as part of the glycerol-3-phosphate oxidase system (see Fig 4A, left-hand panels). Consistent with a glycerol-efflux defect, dose-response curves revealed that *aqp1-2-3* null-cells were SHAM-sensitive (EC_{50} decreased >7-fold) relative to wild-type cells (Fig 4A, right-hand panel: EC_{50} 1.6 and 12 μ M, respectively). SHAM plus glycerol rapidly kills bloodstream-form African trypanosomes [27] (see Fig 4B, left-hand panel), but we predicted that the impact of added glycerol would not be pronounced in glycerol-uptake defective *aqp1-2-3* null-cells. Indeed, SHAM dose-response curves generated in the presence of 10 mM glycerol (Fig 4B, right-hand panel) revealed a substantial impact of glycerol against wild-type cells but only a very weak impact against *aqp1-2-3* null-cells; glycerol reduced SHAM EC_{50} values by 13 and 1.8-fold, respectively; to 0.9 μ M in both cases (compare Fig 4A and 4B). We also tested the additional TAO inhibitors, propyl gallate and octyl gallate [28], against wild-type and *aqp1-2-3* null-cells. Once again, and consistent with a glycerol-efflux defect, dose-response curves revealed that *aqp1-2-3* null-cells were TAO inhibitor sensitive relative to wild-type cells (Fig 4C); EC_{50} was reduced by 4-fold and 5-fold, respectively.




Fig 4. *aqp*-null *T. b. brucei* display defective glycerol-efflux and respiratory inhibitor-sensitivity. (A) Bloodstream *T. brucei* express a SHAM-sensitive mitochondrial trypanosome alternative oxidase (TAO). Under aerobic conditions, TAO activity allows ATP production without glycerol production as indicated by the black lines (left-hand blue 'cell'). SHAM blocks TAO-activity, leading to the anaerobic production of glycerol, which is toxic if not removed, as indicated by the black lines (right-hand blue 'cell'). SHAM dose-response curves for wild-type (WT) and *aqp1-2-3* null-cells. EC_{50} values are indicated.

(B) In the presence of SHAM and glycerol, the glycerol inhibits glycerol kinase (GK), also preventing ATP-production by the anaerobic route (blue 'cell'). SHAM dose-response curves as in A but in the presence of 10 mM glycerol. (C) Propyl gallate and octyl gallate dose-response curves for wild-type (WT) and *aqp1-2-3* null-cells. EC₅₀ values are indicated. (D) SHAM EC₅₀ values +/- 10 mM glycerol from A-B and also from *aqp2*, *aqp2-3* and *aqp1-2-3* cells re-expressing ^{GFP}AQP2. * indicates significantly different ($P < 0.01$) to WT using an ANOVA test in GraphPad Prism. Pairwise comparisons +/- glycerol, except in the case of the *aqp1-2-3* null, indicated significant ($P < 0.001$) differences using a Student's *t*-test. Error bars, SD. The images to the right show re-expression of ^{GFP}AQP2 in *aqp1-2-3* null-cells.

<https://doi.org/10.1371/journal.ppat.1006307.g004>

Since our glycerol-utilisation assays indicated a defect in *aqp2* null *T. b. brucei*, we next asked whether these cells also displayed increased sensitivity to SHAM, consistent with a glycerol-efflux defect. We also tested SHAM-sensitivity in *aqp2-3* null cells and in *aqp1-2-3* null cells re-expressing AQP2; re-expressed AQP2 was localised to the flagellar pocket (Fig 4D, right-hand side), as expected [9]. The full set of SHAM (plus glycerol) EC₅₀ values are shown in Fig 4D. SHAM-sensitivity was indeed observed in *aqp2* null (2.4-fold) *aqp2-3* null (3.2-fold) and *aqp1-2-3* null cells (see above); these cells were all significantly more sensitive to SHAM than wild type (Fig 4D), and AQP2 re-expression effectively reversed SHAM-sensitivity in the *aqp1-2-3* null background (Fig 4D). Also, 10 mM glycerol reduced SHAM EC₅₀ values to <1 μM in all cell types and this reduction was significant in all but the *aqp1-2-3* null cells (Fig 4D), again consistent with almost complete ablation of glycerol transport in the latter case only.

Melarsoprol-resistant clinical isolates display respiratory inhibitor-sensitivity

TAO inhibitor-sensitivity in *aqp*-null *T. b. brucei* may help to predict how trypanosomes in patients will respond to respiratory inhibitors. In particular, naturally occurring melarsoprol-resistant clinical *T. b. gambiense* isolates display chimerisation of the AQP2/3 genes [14]. Indeed, a substantial proportion, >50% in some areas, of circulating *T. b. gambiense* may be AQP2-defective [12,13]; probably due to selection with melarsoprol since the 1940s. To analyse whether this AQP2 defect might have an impact on respiratory inhibitor-sensitivity in clinical isolates, we generated SHAM dose-response curves. The isolates selected were the melarsoprol/pentamidine sensitive STIB930 and STIB891 strains (EC₅₀ <10 and <2 nM, respectively, according to [12]), the melarsoprol/pentamidine resistant K03048 and 40 AT isolates from melarsoprol-relapsed patients (EC₅₀ >20 and >50 nM, respectively, according to [12]) and a 40 AT-derivative that re-expresses AQP2 and is consequently restored to melarsoprol/pentamidine sensitivity [14]. The STIB930 and STIB891 strains are from patients in Côte d'Ivoire in 1978 [29] and Uganda in 1995 [30] and the K03048 and 40 AT isolates are from patients in South Sudan in 2003 [31] and the Democratic Republic of the Congo in 2006 [13], respectively. The STIB930 and STIB891 strains have intact AQP2 genes, while neither of the latter isolates has an intact AQP2 gene [12].

As our studies on *T. b. brucei* had predicted, dose-response curves for the *T. b. gambiense* strains revealed significantly lower EC₅₀ values for both *aqp2*-defective strains relative to the AQP2 controls (Fig 5A); the strains that lacked AQP2 were also confirmed to be pentamidine-resistant (Fig 5A, inset), as previously reported [12]. These results suggest a glycerol-efflux defect in the *aqp2*-defective clinical isolates. Re-expression of AQP2 in 40 AT cells did not significantly alter SHAM-sensitivity, however (Fig 5A). This may indicate that the AQP2/3 chimera interferes with glycerol efflux by recombinant AQP2, possibly due to the formation of AQP hetero-tetramers that, despite the glycerol efflux defect, continue to contribute to pentamidine uptake by endocytosis [22]. The addition of 10 mM glycerol significantly reduced SHAM EC₅₀ values to <1 μM in all five cell-types (Fig 5A), indicating, as predicted, continued




Fig 5. Respiratory inhibitor-sensitivity in *T. b. gambiense* isolates and AQP-mediated glycerol transport. (A) SHAM EC₅₀ values for the *T. b. gambiense* strains are indicated +/- glycerol. The inset shows pentamidine EC₅₀ values. * indicates significantly different ($P < 0.05$) to STIB930 using an ANOVA test in GraphPad Prism. All pairwise comparisons +/- 10 mM glycerol also indicated significant ($P < 0.001$) differences using a Student's *t*-test. Error bars, SD. (B) Propyl gallate and (C) Ascofuranone EC₅₀ values. Other details as in A. (D) Model for glycerol transport by AQPs in *T. b. gambiense*. The weight of the arrows indicates relative impact on glycerol utilisation and efflux, with AQP2 being the major contributor; note that transport across both the plasma and glycosomal membranes contributes to glycerol utilisation and efflux, see the text for more details. The right-hand panel indicates the situation in melarsoprol-resistant (reduced melarsoprol uptake) and SHAM-sensitive (reduced glycerol efflux) clinical isolates where a chimeric AQP2/3 replaces AQP2 and AQP3.

<https://doi.org/10.1371/journal.ppat.1006307.g005>

glycerol influx in each case. To extend these findings, we examined the impact of two additional TAO inhibitors, propyl gallate and ascofuranone [32], on the same set of strains described above. Dose-responses for propyl gallate (Fig 5B) and ascofuranone (Fig 5C) revealed similar EC₅₀ profiles as detailed above for SHAM. Although the STIB891 EC₅₀ for propyl gallate was relatively low, both *aqp2*-defective strains displayed an even lower EC₅₀, and both were significantly more sensitive to the respiratory inhibitors than the STIB930 control (Fig 5B and 5C). Once again, re-expression of *AQP2* in 40 AT cells did not significantly alter respiratory inhibitor sensitivity (Fig 5B and 5C).

Together, our results indicate that triple *aqp*-null and *aqp2* null *T. b. brucei* exhibit defects in bidirectional glycerol flux. The evidence is three-fold; first, failure to take up or effectively utilise glycerol as a carbon source; second, sensitivity to multiple respiratory inhibitors which produce toxic levels of intracellular glycerol; and third, no significant increase in SHAM-

sensitivity in excess glycerol in triple-null cells. Thus, glycerol flux appears to be almost absent in *aqp1-2-3* triple-null cells. Our results also indicate that AQP2 makes a key contribution to glycerol utilisation and efflux. This interpretation is supported by a substantial defect in glycerol utilisation and sensitivity to SHAM in *aqp2* null-cells; a phenotype that is reversed by AQP2 re-expression in *aqp1-2-3* triple-null cells. Importantly, analysis of melarsoprol/pentamidine sensitive *T. b. gambiense* reference strains and melarsoprol/pentamidine resistant clinical-isolates supports the idea that AQP2 also makes a key contribution to glycerol efflux in trypanosomes in patients (see Fig 5D). We propose that it is the replacement of AQP2 with the AQP2-3 chimera in clinical isolates (Fig 5D) that increases sensitivity to respiratory inhibitors. Notably, although the chimera comprises <15% of the AQP3-sequence at the C-terminus, like AQP3 [9], the chimera is distributed within the plasma membrane [10]; AQP2 by contrast is concentrated in the flagellar pocket in bloodstream-form cells [9].

Discussion

Here, we describe bloodstream-form *T. b. brucei* strains that lack all three AQPs. These strains exhibit only a minimal fitness-defect and no apparent osmoregulation-defect. They do, however, exhibit bidirectional defects in glycerol transport. AQP2 is an important determinant of cross-resistance to melarsoprol and pentamidine and this AQP was also found to make a key contribution to glycerol transport. Finally, following analysis of clinical isolates, we propose that the AQPs behave similarly in parasites in patients, suggesting that TAO-inhibitors may be more effective against melarsoprol-resistant African trypanosome infections.

The triple *aqp*-null strain was assembled with the primary purpose of dissecting AQP-functions. We note though that successful generation of such a strain indicates that the AQPs are unlikely to be suitable therapeutic targets for inhibition. It was also possible to generate malaria parasites that lacked the single encoded AQP gene; these *aqp*-null *Plasmodium* parasites displayed defective glycerol uptake and moderately reduced virulence [33]. We find that *aqp1-2-3* null *T. b. brucei* establish parasitemia in mice. Indeed, strains isolated from patients following melarsoprol treatment-failure, in an area where treatment-failure is common, display fusion of AQP2 and AQP3 to form an AQP2/3 chimera [12,13]. This suggests, either that these AQPs are dispensable at all stages of the life-cycle, or that the chimera complements the defect(s). It remains possible that AQP1 or the AQP2/3 chimera have essential functions in other life-cycle stages, but we were able to differentiate triple-null cells to the procyclic stage *in vitro* and also note that *T. vivax* and *T. congolense* appear to lack both the AQP1 and AQP2 genes [34].

The three *T. b. brucei* AQPs were previously reported to play a role in osmoregulation [16]. The same study indicated an additional glycerol transport activity in *T. b. brucei* [16]. In contrast, we observe minimal or no defect in osmoregulation and detected minimal residual glycerol flux in triple *aqp*-null cells. The former difference could potentially reflect adaptation in null cells but the latter difference is likely explained by only 36% AQP2 knockdown or 73% triple AQP knockdown in the former study [16]. Notably, adaptation, if it operates, would also be expected in clinical and veterinary isolates that lack AQP genes. How is osmoregulation achieved in other parasitic trypanosomatids? A contractile vacuole/spongione complex is present in *Trypanosoma cruzi* and *Leishmania major*, and aqua(glycero)porins have been localised to these organelles [35,36]; the *T. cruzi* aquaporin is not closely related to the *T. brucei* AQPs but *Leishmania* AQP1 is closely related [6] and does play a role in osmoregulation [37]. However, water can diffuse across membranes and alternative mechanisms of osmoregulation do operate. In both *L. major* [38] and *Crithidia luciliae* [39], cells tolerate hypotonic stress through the efflux of amino acids and, in *Leishmania donovani*, also through the efflux of inorganic osmolytes [40]. Thus, *T. brucei* AQPs may contribute to osmoregulation, but we suggest

that the primary roles of these AQPs in bloodstream-form cells are the transport of glycerol and other solutes.

Under aerobic conditions, *T. b. brucei* can use glycerol as a carbon source [41]. We found that triple *aqp*-null cells, and even *aqp2*-null cells, fail to effectively utilise glycerol. This indicates that AQPs contribute to glycerol-uptake and utilisation and that AQP2 makes a key contribution. Since glycerol utilisation and production under anaerobic conditions occurs inside glycosomes [25], we must consider glycosomal transport as well as transport across the plasma membrane. A *T. cruzi* aquaporin is localised to acidocalcisomes [36] but AQPs have not been reported to be associated with glycosomes. It is possible that the *T. brucei* AQPs are also present in glycosomal membranes but there may equally be alternative glycerol transporters associated with these organelles.

Carbohydrate catabolism in African trypanosomes has been considered a promising potential antitrypanosomal therapeutic target for >40 years. Indeed, a SHAM plus glycerol combination blocks aerobic and anaerobic glycolysis *in vivo* and clears parasites from the blood of experimental animals within 5 min [27]. Since this combination is so effective, glycerol-efflux has remained of particular interest [26]. SHAM inhibits TAO, which is upregulated in the bloodstream-form and not found in other trypanosomatids or in the mammalian host [26]. TAO inhibition blocks the aerobic pathway and increases the production of ATP via the reverse-action of glycerol kinase [41]. The glycerol produced by this anaerobic glycolysis will become toxic if not removed from the cell. If glycerol is not removed, it reverses the action of glycerol kinase by mass-action and also blocks the anaerobic pathway, explaining the toxic effect of SHAM plus glycerol. Our findings indicate that this SHAM-glycerol effect is dependent upon the AQPs. Indeed, our results show that *aqp2*, *aqp2-3* and *aqp1-2-3* cells, and clinical isolates lacking AQP2 but with an AQP2/3 chimera, display increased sensitivity to multiple respiratory inhibitors in the absence of exogenous glycerol. Thus, AQP2 plays a key role in both glycerol utilisation and efflux.

The combination of SHAM with a large dose of glycerol, required at up to 15 g per kg, remains impractical as a therapy [42]. More potent antitrypanosomal TAO inhibitors have been developed, however [42,43,44]. Our finding, therefore, that *aqp2*-deficiency is associated with TAO-inhibitor sensitivity, has implications for potential future therapeutic strategies. For example, new TAO-inhibitors may be effective as mono-therapies against melarsoprol-resistant *T. b. rhodesiense* [4], or *T. b. gambiense*, known to lack AQP2 in the latter case [12]. This may also be the case for *T. vivax* and *T. congolense*, where the reference genomes indicate the absence of both the AQP1 and AQP2 genes and the presence of only an AQP3-like gene (Tv486_1013610 and TcIL3000_10_12040, respectively) [34]. Indeed, although SHAM alone is ineffective against *T. vivax* [45], ascofuranone is effective against *T. vivax* infections in mice without added glycerol [32]. This and other TAO inhibitors are thought to function by mimicking ubiquinol and blocking electron transfer to the oxidase [46].

Melarsoprol has been highly effective against trypanosomiasis but clinical resistance, due to an *aqp2*-defect, has become widespread [12]. An option, therefore, could be to apply TAO-inhibitors and melarsoprol sequentially or in combination; this could establish a counter-resistance approach whereby AQP2 is required for both the uptake and efflux of toxins. Further similar options may emerge from on-going efforts to develop safer and orally available arsenical formulations [47]. Ultimately, reciprocal shifts in drug-sensitivity, such as the example we describe here, may be exploited to develop novel paradigms of targeted-therapy. Such strategies could restrict or even reverse the emergence and spread of drug resistance in human and livestock parasites, which would be of great value given the high cost of developing new therapies.

Our studies on *aqp*-null *T. b. brucei* and on clinical isolates of *T. b. gambiense* have revealed bidirectional defects in glycerol transport and the key contribution of AQP2, the AQP

specifically responsible for melarsoprol- and pentamidine-sensitivity, now also shown to impact respiratory inhibitor sensitivity. Thus, AQPs impact the efficacy of three major classes of antitrypanosomal drugs. These new mechanistic insights into differential sensitivities to antitrypanosomal drugs, in both clinical and veterinary settings, are potentially exploitable.

Materials and methods

T. b. brucei growth and manipulation

Bloodstream-form *T. brucei*, Lister 427, MiTat 1.2, clone 221a, and all derivatives were cultured in HMI-11 as previously described [48]. Bloodstream-form *T. b. gambiense* were cultured in the same media but with 15% FCS and 5% human serum. 2T1 [24], *aqp2* [9], *aqp2-3* [23], STIB930, STIB891, K03048, 40 AT [12] and 40 AT plus AQP2 [14] strains were described previously. SHAM, glycerol, octyl gallate and propyl gallate were from Sigma. SHAM was dissolved in DMSO, the gallates were dissolved in 70% ethanol or DMSO and ascofuranone was dissolved in DMSO. EC₅₀ assays were performed using the AlamarBlue method as described [49] with 10 mM glycerol added as appropriate; drug exposure was for 66–67 h and Alamar-Blue incubation was for 5–6 h. Plates were read on an Infinite 200 Pro plate-reader (Tecan). Growth rates in culture were monitored by splitting to 1 x 10⁵ cells/ml and by counting daily. Three Balb/c mice were infected with *aqp1-2-3* triple-null trypanosomes by intraperitoneal injection of 10⁴ cells in 0.2 ml of growth medium. Parasitaemia was determined daily following tail bleeds. Mice were purchased from Envigo, UK. Differentiation to insect-stage, procyclic form cells was initiated by washing 2 x 10⁷ cells twice in DTM [50] and re-suspending in 5 ml DTM supplemented with citrate (3 mM) and cis-aconitate (3 mM) at 27°C.

Plasmids and strain construction

For AQP-knockout plasmid constructs, AQP-flanking sequences were inserted on both sides of selectable marker cassettes. Restriction enzyme cleavage at the distal ends of the AQP targeting regions was used to linearise plasmid constructs prior to transfection. The AQP2-3 locus was disrupted by replacing a 4,772 bp fragment [9] with *BLA* and a modified *NPT* selectable marker cassette. The *AQP1* locus was disrupted by replacing a 647 bp fragment with *NPT* and (a modified) *PAC* selectable marker cassettes. The *AQP1:PAC* and *AQP2-3:NPT* cassettes were modified using annealed oligonucleotides (XScF: CTAGTAGGGATAACAGGGTAAT, and XScR: CTAGGATTACCTGTTATCCCTA) to engineer an I-*SceI* site at an *XbaI* site adjacent to each 5'-targeting region. Other oligonucleotide sequences are available upon request.

During creation of the *aqp1-2-3* triple-null strains, selectable markers were recovered using I-*SceI* meganuclease-induction in a 2T1 (*BLE:PAC*) background [48]. Briefly, a pRPa^{Sce} [51] construct (*HYG* recovers *PAC*) was introduced at the tagged locus on chromosome 2 and the *AQP2-3* alleles were replaced with *BLA* and *NPT*-cassettes, the latter containing the flanking I-*SceI* cleavage site. Induction with 1 μg.ml⁻¹ tetracycline triggered I-*SceI* cleavage and duplication of the *BLA*-cassette (*NPT* recovered). A similar process was repeated for *AQP1* alleles but this time with *NPT* and *PAC*-cassettes (*PAC* recovered). The ph3E construct [48] was then used to remove the I-*SceI* cassette (*PAC* recovered *HYG*). A pRPa^{AQP2} construct (*HYG* recovers *PAC*) was then used for expression of recombinant *AQP2* in the 2T1-*aqp1-2-3* null-background (*BLE:BLA:NEO:PAC*). Selectable-marker recovery was confirmed by screening individual clones in multi-well plates. Strains were transfected using a Nucleofector (Lonza) and cytomix. Transformants were selected with phleomycin (1 μg.ml⁻¹), blasticidin (10 μg.ml⁻¹), G418 (2 μg.ml⁻¹), puromycin (2 μg.ml⁻¹) and hygromycin (2.5 μg.ml⁻¹) as appropriate and AQP knockout was confirmed by Southern blotting, carried out according to standard protocols.

Hypo-osmotic shock assays

Cell volume during hypo-osmotic shock was assessed using a light-scattering assay. Briefly, 5×10^7 cells were pelleted and resuspended in ice cold Earle's salt buffer (116 mM NaCl, 1.8 mM CaCl_2 , 5 mM KCl, 0.8 mM MgSO_4 , 1 mM NaH_2PO_4 , 30 mM HEPES, 30 mM glucose, pH 7.4). 1.3×10^4 cells in 100 μl per well were added to 96-well plates. Either 100 μl of cold deionised water (hypo-osmotic) or Earle's salt buffer (iso-osmotic) was added to each well. Results were then immediately read at 18-s intervals over a course of 25-min, using a Tecan Infinite 200 pro plate-reader at 595 nM absorbance.

Microscopy

For phase and fluorescence microscopy, cells were fixed in 1% paraformaldehyde, settled onto slides and mounted in Vectashield (Vector Laboratories) containing 4,6-diamidino-2-phenylindole (DAPI). Images were captured using an Axiovert 200 epifluorescence microscope in conjunction with an Axiocam 105 colour camera (Zeiss) and were processed using Zen digital imaging suite.

ATP quantification

We used the CellTiter-Glo luminescence assay (Promega). Briefly 5×10^6 cells were washed twice with cold PBS and re-suspended in 1 ml of 37°C PBS with either 5 mM glucose or glycerol in PBS for 20-min before performing the assay as per the manufacturers' instructions. Plates were read on an Infinite 200 Pro plate-reader (Tecan). Values were compared to an ATP standard-curve.

Glycerol uptake assay

We used a [^{14}C] glycerol centrifugation method [52] with minor modifications. Briefly, cells were pelleted by centrifugation (1,000 g, 10 min), washed twice in transport buffer (33 mM HEPES, 98 mM NaCl, 4.6 mM KCl, 0.55 CaCl_2 , 0.07 MgSO_4 , 5.8 mM Na_2PO_4 , 0.3 mM NaHCO_3 , 14 mM glucose, pH 7.3) and diluted to $1 \times 10^8/\text{ml}$ in transport buffer on ice. Uptake was measured (at 37°C) by introducing 100 μl of cells to 100 μl transport buffer, containing 0.25 uCi glycerol. This reaction mixture was immediately loaded onto 100 μl of dibutyl phthalate (Sigma) in 1.5 ml Eppendorf tubes. After incubation for 5 min, cells were pelleted through the oil layer by centrifugation (16,000g, 1 min). The tubes were then frozen on liquid nitrogen and the bottoms of the tubes, containing pellets, were snipped directly into scintillation vials. Pellets were solubilised overnight in 150 μl 1 M NaOH, before mixing with 2 ml of scintillation fluid and reading on a scintillation counter (Beckman LS 6500) for 1 min.

Ethics statement

All animal experiments were approved by the Ethical Review Committee at the University of Dundee and performed under the Animals (Scientific Procedures) Act 1986 (UK Home Office Project Licence PPL 70/8274) in accordance with the European Communities Council Directive (86/609/EEC).

Acknowledgments

We thank L. Glover (Institut Pasteur) for advice on meganuclease cleavage, A. Fairlamb and N. Sienkiewicz (University of Dundee) for advice on glycerol uptake and utilisation assays, the TrypTag team (University of Oxford) for permission to cite data from their website (TrypTag.com) and B. Dujon (Institut Pasteur) for the I-SceI gene.

Author Contributions

Conceptualization: LJ NB NW PM DH.

Investigation: LJ NB NW.

Supervision: PM DH.

Writing – original draft: LJ NB DH.

Writing – review & editing: LJ DH.

References

1. Brun R, Blum J, Chappuis F, Burri C (2010) Human African trypanosomiasis. *Lancet* 375: 148–159. [https://doi.org/10.1016/S0140-6736\(09\)60829-1](https://doi.org/10.1016/S0140-6736(09)60829-1) PMID: 19833383
2. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African *Trypanosoma brucei gambiense* trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. *Lancet* 374: 56–64. [https://doi.org/10.1016/S0140-6736\(09\)61117-X](https://doi.org/10.1016/S0140-6736(09)61117-X) PMID: 19559476
3. Iten M, Mett H, Evans A, Enyaru JC, Brun R, et al. (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of *Trypanosoma brucei rhodesiense* to D,L- α -difluoromethylornithine. *Antimicrob Agents Chemother* 41: 1922–1925. PMID: 9303385
4. Kibona SN, Matemba L, Kaboya JS, Lubega GW (2006) Drug-resistance of *Trypanosoma b. rhodesiense* isolates from Tanzania. *Trop Med Int Health* 11: 144–155. <https://doi.org/10.1111/j.1365-3156.2005.01545.x> PMID: 16451338
5. Robays J, Nyamowala G, Sese C, Betu Ku Mesu Kande V, Lutumba P, et al. (2008) High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. *Emerg Infect Dis* 14: 966–967. <https://doi.org/10.3201/eid1406.071266> PMID: 18507916
6. Baker N, de Koning HP, Maser P, Horn D (2013) Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. *Trends Parasitol* 29: 110–118. <https://doi.org/10.1016/j.pt.2012.12.005> PMID: 23375541
7. Carter NS, Fairlamb AH (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. *Nature* 361: 173–176. <https://doi.org/10.1038/361173a0> PMID: 8421523
8. Maser P, Sutterlin C, Kralli A, Kaminsky R (1999) A nucleoside transporter from *Trypanosoma brucei* involved in drug resistance. *Science* 285: 242–244. PMID: 10398598
9. Baker N, Glover L, Munday JC, Aguinaga Andres D, Barrett MP, et al. (2012) Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. *Proc Natl Acad Sci U S A* 109: 10996–11001. <https://doi.org/10.1073/pnas.1202885109> PMID: 22711816
10. Munday JC, Eze AA, Baker N, Glover L, Clucas C, et al. (2014) *Trypanosoma brucei* aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. *J Antimicrob Chemother* 69: 651–663. <https://doi.org/10.1093/jac/dkt442> PMID: 24235095
11. Bronner U, Gustafsson LL, Doua F, Ericsson O, Miezian T, et al. (1995) Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with *Trypanosoma gambiense* sleeping sickness. *British Journal of Clinical Pharmacology* 39: 289–295. PMID: 7619671
12. Graf FE, Ludin P, Wenzler T, Kaiser M, Brun R, et al. (2013) Aquaporin 2 mutations in *Trypanosoma brucei gambiense* field isolates correlate with decreased susceptibility to pentamidine and melarsoprol. *PLoS Negl Trop Dis* 7: e2475. <https://doi.org/10.1371/journal.pntd.0002475> PMID: 24130910
13. Pyana Pati P, Van Reet N, Mumba Ngoyi D, Ngay Lukusa I, Karhemere Bin Shamamba S, et al. (2014) Melarsoprol sensitivity profile of *Trypanosoma brucei gambiense* isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo. *PLoS Negl Trop Dis* 8: e3212. <https://doi.org/10.1371/journal.pntd.0003212> PMID: 25275572
14. Graf FE, Baker N, Munday JC, de Koning HP, Horn D, et al. (2015) Chimerization at the *AQP2-AQP3* locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical *Trypanosoma brucei gambiense* isolates. *Int J Parasitol Drugs Drug Resist* 5: 65–68. <https://doi.org/10.1016/j.ijpddr.2015.04.002> PMID: 26042196
15. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, et al. (2004) Drug uptake and modulation of drug resistance in *Leishmania* by an aquaglyceroporin. *J Biol Chem* 279: 31010–31017. <https://doi.org/10.1074/jbc.M403959200> PMID: 15138256

16. Bassarak B, Uzcategui NL, Schonfeld C, Duszenko M (2011) Functional characterization of three aquaglyceroporins from *Trypanosoma brucei* in osmoregulation and glycerol transport. *Cell Physiol Biochem* 27: 411–420. <https://doi.org/10.1159/000327968> PMID: 21471730
17. Dean S, Sunter JD, Wheeler RJ (2017) TrypTag.org: A Trypanosome Genome-wide Protein Localization Resource. *Trends Parasitol* 33: 80–82. <https://doi.org/10.1016/j.pt.2016.10.009> PMID: 27863903
18. Zeuthen T, Wu B, Pavlovic-Djuranovic S, Holm LM, Uzcategui NL, et al. (2006) Ammonia permeability of the aquaglyceroporins from *Plasmodium falciparum*, *Toxoplasma gondii* and *Trypanosoma brucei*. *Mol Microbiol* 61: 1598–1608. <https://doi.org/10.1111/j.1365-2958.2006.05325.x> PMID: 16889642
19. Marsiccobetre S, Rodriguez-Acosta A, Lang F, Figarella K, Uzcategui NL (2017) Aquaglyceroporins Are the Entry Pathway of Boric Acid in *Trypanosoma brucei*. *Biochim Biophys Acta* 1859: 679–685. <https://doi.org/10.1016/j.bbame.2017.01.011> PMID: 28087364
20. Uzcategui NL, Szallies A, Pavlovic-Djuranovic S, Palmada M, Figarella K, et al. (2004) Cloning, heterologous expression, and characterization of three aquaglyceroporins from *Trypanosoma brucei*. *J Biol Chem* 279: 42669–42676. <https://doi.org/10.1074/jbc.M404518200> PMID: 15294911
21. Uzcategui NL, Figarella K, Bassarak B, Meza NW, Mukhopadhyay R, et al. (2013) *Trypanosoma brucei* aquaglyceroporins facilitate the uptake of arsenite and antimonite in a pH dependent way. *Cell Physiol Biochem* 32: 880–888. <https://doi.org/10.1159/000354490> PMID: 24217645
22. Song J, Baker N, Rothert M, Henke B, Jeacock L, et al. (2016) Pentamidine Is not a permeant but a nanomolar inhibitor of the *Trypanosoma brucei* aquaglyceroporin-2. *PLoS Pathog* 12: e1005436. <https://doi.org/10.1371/journal.ppat.1005436> PMID: 26828608
23. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, et al. (2012) High-throughput decoding of antitrypanosomal drug efficacy and resistance. *Nature* 482: 232–236. <https://doi.org/10.1038/nature10771> PMID: 22278056
24. Alsford S, Horn D (2008) Single-locus targeting constructs for reliable regulated RNAi and transgene expression in *Trypanosoma brucei*. *Mol Biochem Parasitol* 161: 76–79. <https://doi.org/10.1016/j.molbiopara.2008.05.006> PMID: 18588918
25. Haanstra JR, van Tuijl A, Kessler P, Reijnders W, Michels PA, et al. (2008) Compartmentation prevents a lethal turbo-explosion of glycolysis in trypanosomes. *Proc Natl Acad Sci U S A* 105: 17718–17723. <https://doi.org/10.1073/pnas.0806664105> PMID: 19008351
26. Chaudhuri M, Ott RD, Hill GC (2006) Trypanosome alternative oxidase: from molecule to function. *Trends Parasitol* 22: 484–491. <https://doi.org/10.1016/j.pt.2006.08.007> PMID: 16920028
27. Clarkson AB Jr., Brohn FH (1976) Trypanosomiasis: an approach to chemotherapy by the inhibition of carbohydrate catabolism. *Science* 194: 204–206. PMID: 986688
28. Grady RW, Bienen EJ, Clarkson AB Jr., (1986) Esters of 3,4-dihydroxybenzoic acid, highly effective inhibitors of the sn-glycerol-3-phosphate oxidase of *Trypanosoma brucei*. *Mol Biochem Parasitol* 21: 55–63. PMID: 3773935
29. Felgner P, Brinkmann U, Zillmann U, Mehlitz D, Abu-Ishira S (1981) Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part II. Parasitological and immunodiagnostic examination of the human population. *Tropenmedizin und Parasitologie* 32: 134–140. PMID: 6285560
30. Matovu E, Geiser F, Schneider V, Maser P, Enyaru JC, et al. (2001) Genetic variants of the *TbAT1* adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. *Mol Biochem Parasitol* 117: 73–81. PMID: 11551633
31. Maina NW, Oberle M, Otieno C, Kunz C, Maeser P, et al. (2007) Isolation and propagation of *Trypanosoma brucei gambiense* from sleeping sickness patients in south Sudan. *Trans R Soc Trop Med Hyg* 101: 540–546. <https://doi.org/10.1016/j.trstmh.2006.11.008> PMID: 17275053
32. Yabu Y, Suzuki T, Nihei C, Minagawa N, Hosokawa T, et al. (2006) Chemotherapeutic efficacy of ascocofuranone in *Trypanosoma vivax*-infected mice without glycerol. *Parasitol Int* 55: 39–43. <https://doi.org/10.1016/j.parint.2005.09.003> PMID: 16288933
33. Promeneur D, Liu Y, Maciel J, Agre P, King LS, et al. (2007) Aquaglyceroporin PbaQP during intraerythrocytic development of the malaria parasite *Plasmodium berghei*. *Proc Natl Acad Sci U S A* 104: 2211–2216. <https://doi.org/10.1073/pnas.0610843104> PMID: 17284593
34. Jackson AP, Berry A, Aslett M, Allison HC, Burton P, et al. (2012) Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species. *Proc Natl Acad Sci U S A* 109: 3416–3421. <https://doi.org/10.1073/pnas.1117313109> PMID: 22331916
35. Figarella K, Uzcategui NL, Zhou Y, LeFurgey A, Ouellette M, et al. (2007) Biochemical characterization of *Leishmania major* aquaglyceroporin LmAQP1: possible role in volume regulation and osmotaxis. *Mol Microbiol* 65: 1006–1017. <https://doi.org/10.1111/j.1365-2958.2007.05845.x> PMID: 17640270

36. Montalvetti A, Rohloff P, Docampo R (2004) A functional aquaporin co-localizes with the vacuolar proton pyrophosphatase to acidocalcisomes and the contractile vacuole complex of *Trypanosoma cruzi*. *J Biol Chem* 279: 38673–38682. <https://doi.org/10.1074/jbc.M406304200> PMID: 15252016
37. Plourde M, Ubeda JM, Mandal G, Monte-Neto RL, Mukhopadhyay R, et al. (2015) Generation of an aquaglyceroporin AQP1 null mutant in *Leishmania major*. *Mol Biochem Parasitol* 201: 108–111. <https://doi.org/10.1016/j.molbiopara.2015.07.003> PMID: 26222914
38. Vieira LL, Lafuente E, Gamarro F, Cabantchik Z (1996) An amino acid channel activated by hypotonically induced swelling of *Leishmania major* promastigotes. *Biochem J* 319 (Pt 3): 691–697. PMID: 8920968
39. Bursell JD, Kirk J, Hall ST, Gero AM, Kirk K (1996) Volume-regulatory amino acid release from the protozoan parasite *Crithidia luciliae*. *J Membrane Biol* 154: 131–141.
40. Lefurgey A, Gannon M, Blum J, Ingram P (2005) *Leishmania donovani* amastigotes mobilize organic and inorganic osmolytes during regulatory volume decrease. *The J Euk Microbiol* 52: 277–289. <https://doi.org/10.1111/j.1550-7408.2005.00030.x> PMID: 15927005
41. Bakker BM, Michels PA, Opperdoes FR, Westerhoff HV (1997) Glycolysis in bloodstream form *Trypanosoma brucei* can be understood in terms of the kinetics of the glycolytic enzymes. *J Biol Chem* 272: 3207–3215. PMID: 9013556
42. Nihei C, Fukai Y, Kita K (2002) Trypanosome alternative oxidase as a target of chemotherapy. *Biochim Biophys Acta* 1587: 234–239. PMID: 12084465
43. Grady RW, Bienen EJ, Dieck HA, Saric M, Clarkson AB Jr. (1993) *N*-n-alkyl-3,4-dihydroxybenzamides as inhibitors of the trypanosome alternative oxidase: activity *in vitro* and *in vivo*. *Antimicrob Agents Chemother* 37: 1082–1085. PMID: 8517695
44. Menzies SK, Tulloch LB, Florence GJ, Smith TK (2016) The trypanosome alternative oxidase: a potential drug target? *Parasitology*: 1–9.
45. Evans DA, Holland MF (1978) Effective treatment of *Trypanosoma vivax* infections with salicylhydroxamic acid (SHAM). *Trans R Soc Trop Med Hyg* 72: 203–204. PMID: 653794
46. Shiba T, Kido Y, Sakamoto K, Inaoka DK, Tsuge C, et al. (2013) Structure of the trypanosome cyanide-insensitive alternative oxidase. *Proc Natl Acad Sci U S A* 110: 4580–4585. <https://doi.org/10.1073/pnas.1218386110> PMID: 23487766
47. Kennedy PG (2012) An alternative form of melarsoprol in sleeping sickness. *Trends Parasitol* 28: 307–310. <https://doi.org/10.1016/j.pt.2012.05.003> PMID: 22704910
48. Alsford S, Kawahara T, Glover L, Horn D (2005) Tagging a *T. brucei* *RRNA* locus improves stable transfection efficiency and circumvents inducible expression position effects. *Mol Biochem Parasitol* 144: 142–148. <https://doi.org/10.1016/j.molbiopara.2005.08.009> PMID: 16182389
49. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (*T. b. rhodesiense* and *T. b. gambiense*) *in vitro*. *Acta Trop* 68: 139–147. PMID: 9386789
50. Czichos J, Nonnengaesser C, Overath P (1986) *Trypanosoma brucei*: *cis*-aconitate and temperature reduction as triggers of synchronous transformation of bloodstream to procyclic trypomastigotes *in vitro*. *Exp Parasitol* 62: 283–291. PMID: 3743718
51. Alsford S, Turner DJ, Obado SO, Sanchez-Flores A, Glover L, et al. (2011) High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome. *Genome Res* 21: 915–924. <https://doi.org/10.1101/gr.115089.110> PMID: 21363968
52. Wille U, Schade B, Duszenko M (1998) Characterization of glycerol uptake in bloodstream and procyclic forms of *Trypanosoma brucei*. *Eur J Biochem* 256: 245–250. PMID: 9746370